Immune Tolerance Network

News and Press

Contact Information



	\| Public Access Site for Researchers \|

Islet Transplantation

	Multicenter trial of solitary islet transplantation in type 1 diabetic patients using the Edmonton protocol of steroid-free immunosuppression Principal Investigator: James Shapiro, University of Alberta, Edmonton, Canada

	Evaluation of the tolerogenic efficacy of hOKT3gamma-1 (ala-ala) and sirolimus immunotherapy in Type 1 diabetic islet allograft recipients Principal Investigator: Bernhard Hering, University of Minnesota, Minneapolis, MN

Solid Organ Transplantation
	Kidney Transplantation
	Campath-1H/Rapamycin in Renal Transplantation Principal Investigator: Stuart Knechtle, University of Wisconsin Medical School, Madison, WI

	Pilot Study Using Donor Stem Cells and Campath-1H To Induce Renal Transplant Tolerance Principal Investigator: Joshua Miller, University of Miami

	Renal allograft tolerance through mixed chimerism Principal Investigators: David Sachs, Massachusetts General Hospital, Boston, MA A. Benedict Cosimi, Massachusetts General Hospital, Boston, MA

	Mixed Chimerism and Renal Allografting with Non-Myeloablative Conditioning in Patients with End-Stage Renal Failure due to Multiple Myeloma Principal Investigator: Megan Sykes, Massachusetts General Hospital, Boston, MA

	A Pilot Trial of LEA29Y to Facilitate Drug Withdrawal in Renal Transplantation (in development) Principal Investigator: Flavio Vincenti, University of California, San Francisco

	Liver Transplantation
	Immunosuppression Withdrawal for Stable Pediatric Living Donor Liver Transplant Recipients Principal Investigator: Sandy Feng, University of California, San Francisco, CA

	Immunosuppression withdrawal in liver transplant recipients infected with the hepatitis C virus Principal Investigator: Abraham Shaked, University of Pennsylvania, Philidelphia, PA

	Campath 1H induction therapy and immunosuppression withdrawal in liver transplant recipients Principal Investigator: J. Richard Thistlethwaite, University of Chicago

Autoimmune Diseases

	Type 1 Diabetes A Phase II, multiple dose treatment of Type 1 diabetes with hOKT3gamma-1(Ala-Ala) Principal Investigator: Kevan Herold, Columbia University, New York, NY

	Autoantigen vaccination in human Type 1 newly diagnosed diabetes mellitus Principal Investigator: Tihamer Orban, Joslin Diabetes Center, Boston, MA

	Trial Of Thymoglobulin For Treatment Of New Onset Type 1 Diabetes Mellitus Principal Investigator: Stephen Gitleman, University of California, San Francisco, CA

	Multiple Sclerosis Treatment of multiple sclerosis with CTLA4Ig Principal Investigator: Samia Khoury, Brigham & Women's Hospital, Boston, MA

	Atorvastatin therapy in early multiple sclerosis Principal Investigator: Scott Zamvil, University of California, San Francisco

	MRI-Controlled Phase I/II Trial for Treatment of Relapsing MS Using Peptide-Coupled PBL Tolerance Principal Investigator: Stephen D. Miller, Northwestern University, Chicago, IL

	Others Treatment of psoriatic arthritis with hOKT3gamma-1(ala-ala) Principal Investigator: Marcus Clark, University of Chicago, Chicago, IL

	Treatment of Systemic Lupus Erythematosus with CTLA4Ig Principal Investigators: Betty Diamond, Albert Einstein College of Medicine; David Wofsy, University of California, San Francisco

	Rituximab Therapy For The Induction Of Remission and Tolerance In ANCA-Associated Vasculitis Principal Investigators: John Stone, Johns Hopkins University and Ulrich Specks, Mayo Clinic

Allergy & Asthma

	Allergen ISS conjugates in allergic rhinitis Principal Investigator: Peter Creticos, Johns Hopkins University, Baltimore, MD

	Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with Omalizumab, an anti-IgE Monoclonal Antibody Principal Investigator: Thomas B. Casale, Creighton University School of Medicine

	Prophylaxis of atopy and asthma in children Principal Investigator: Patrick G. Holt, University of Western Australia, Perth, AUS

	Allergen ISS conjugates in ragweed-induced asthma Principal Investigator: David H. Broide, University of California, San Diego, CA

	Induction of tolerance through early introduction of peanut in ‘high risk’ children (in development) Principal Investigator: Gideon Lack, Imperial College, London, UK

Home | Terms | © 2002-5 Immune Tolerance Network | Sponsors: NIAID, NIDDK and JDRF | Search